Editorial

• Volume 11 Number 5/6 May/June 2010

Conference reports

• 2nd Joint Conference of BHIVA with BASHH, 20–23 April 2010, Manchester

• HAART use among women in UK receiving treatment prior to conception

• Duration of ruptured membranes and vertical transmission in the UK

• Significant rates of unplanned pregnancies among young women born with HIV

• Route of HCV transmission in HIV-positive gay men is unlikely to be from semen

• 75% HIV-positive children have insufficient levels of Vitamin D

• Increase in LGV cases in gay men reported in the UK

• High rates of osteopenia and osteoporosis: importance of DEXA monitoring

• Summaries of other studies

• 11th International Workshop on Clinical Pharmacology of HIV Therapy, 7-9 April, 2010, Sorrento, Italy

• Atazanavir absorption maximised with food

• Methadone levels reduced moderately by rilpivirine

• Maraviroc 150mg once-daily achieves target concentrations with atazanavir/ritonavir

• Raltegravir and unboosted atazanavir

• Raltegravir dose adjustment not required for patients on dialysis

• Raltegravir and darunavir pharmacokinetics in liver disease

• Tenofovir may require closer renal monitoring in older patients

• Effect of age on atazanavir, darunavir, raltegravir and etravirine

• Proposed approach to measuring TDM for raltegravir

• Increased bilirubin levels when atazanavir is dosed twice-daily

• 17th Conference on Retroviruses and Opportunistic Infections (CROI) 16-19 February 2010, San Francisco

• HIV reinfection cases reported at CROI

• Hepatitis studies: IL28B genetics, HCV survival, FibroScan in acute HCV, MSM reinfection and responses to transplantation

• Poor bioequivalence with crushed and dissolved tablets

• Initial PK, safety and 12 week efficacy of raltegravir chewable tablets in children 6-11 years

• PK of efavirenz in children dosed according to WHO weight bands

• Virological and immunological responses in infants enrolled in the CHER trial

• Darunavir-associated mutations in PI-naive and PI-experienced children in the UK

• HIV persistence, raltegravir/maraviroc intensification and immunology

Antiretrovirals

• START study launched and endorsed by broad community support: over 140 community organisations sign letter to US guideline panel

• FDA safety updates to antiretroviral labels

• Development of apricitabine halted without finding backer for Phase 3

PMTCT and maternal health

• Pregnancy outcomes with efavirenz

Treatment access

• FDA approval of generic ARVs

• U.S. government leading backlash against AIDS funding

• Evidence from six countries confirms fears of People Living With HIV/AIDS: treatment rationing is escalating

• Launch of the 10th funding round and other outcomes from the Global Fund

Basic science and immunology

• The antiviral impact of CD8 T cells: much ado about the mechanism

• Bad to the bone marrow?

• Cell-free vs cell-associated HIV transmission

• Coagulation and inflammatory biomarkers in children and adolescents with HIV

• Pre-infection CD8 T cells targeting HIV linked to lower post-infection viral load

Treatment advocacy

• The HIV Research Catalyst Forum: treatment, prevention, advocacy

• Experimental HCV drugs for HIV/HCV coinfected people: workshop on trial design

• AIDS activists detained by Tanzanian authorities at World Economic Forum on Africa

Other news

• China lifts travel ban on people with HIV

• Malawian court’s 14-year sentence for gay men widely condemned

• Uganda law proposes death penalty for homosexuality: can international reaction and vulnerability of treatment access programmes help?

PDFs

• Volume 11 Number 3/ May/April 2010 PDF